Search
for
Sort by
Research 151–180 of 1000+
- Alopecia Areata
- Eyelash alopecia areata: case series and literature review
- Drug-induced postinfantile giant cell hepatitis
- Symmetrical alopecia in the dog
- What's missing from this picture? An approach to alopecia in children
- Perspectives in Head and Neck Medical Oncology
- 5ARIs and PSA: Evidences
- Manifestaciones dermatológicas asociadas a la gravedad de la infección por COVID-19. Estudio observacional transversal retrospectivo de 144 pacientes
- Alopecia areata and acitretin
- Reply to finasteride and dutasteride may reduce melanoma risk
- Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.
- Hair Disorders
- The cat with alopecia
- Athena: Specialty Certificate Examination case for general dermatology and dermatology in primary healthcare
- Precocious Puberty: A Case Report
- 22-Year-Old Male with Several Discrete Patches of Hair Loss
- Acne Keloidalis Nuchae
- Extensive alopecia areata: A multicenter review of 132 patients
- SARS‐CoV‐2‐induced telogen effluvium: a multicentric study
- Alopecia fibrosante frontal em mulheres negras: aspectos clínicos, diagnósticos e terapêuticos
- Sex- or Gender-specific Differences in the Clinical Presentation, Outcome, and Treatment of SARS-CoV-2
- Connective Tissue Disorders
- Ductal breast cancer in a male patient
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Neurological post‐acute sequelae of SARS‐CoV‐2 infection
- Factors Associated with Severity of Alopecia Areata
- Growth Differentiation Factor 11 (GDF11)/Transforming Growth Factor - β (TGF - β)/Mesenchymal Stem Cells (MSCs) Balance: A Complicated Partnership in Skin Rejuvenation
- Factors Affecting the Response and Patient Satisfaction of Topical Immunotherapy in Alopecia Areata: A Nationwide Study
- Risk factors for prostate cancer: a case-control study investigating selected key exposures and their interactions with predisposition genes
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System